Search - tctmd.com

Displaying 381 - 400 of 406

Sort: Relevancy | Date

News Daily News

Rivaroxaban May be Cost-Effective for A-fib Patients

L.A. McKeown

June 06, 2012

News Daily News

El Rivaroxaban podría ser Rentable en Pacientes con Fibrilación Auricular

L.A. McKeown

June 06, 2012

News Industry News

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

May 23, 2012

News Daily News

New Oral Anticoagulants Top Warfarin in A-fib Stroke Prevention

May 04, 2012

News Daily News

Los Nuevos Anticoagulantes Orales Superan a la Warfarina en la Prevención del ACV en pacientes con Fibrilación Auricular

May 04, 2012

News Daily News

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Caitlin E. Cox

April 26, 2012

News Daily News

ROCKET AF: Interrumpir la Toma de Rivaroxaban o Warfarina es Igual de Perjudicial en Pacientes con Fibrilación Auricular

Caitlin E. Cox

April 26, 2012

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Conference News ACC 2012

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

L.A. McKeown

March 26, 2012

News Daily News

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

L.A. McKeown

January 09, 2012

News Industry News

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

November 04, 2011

News Daily News

Hope Renewed for Novel Anticoagulant Use in ACS

Caitlin E. Cox

October 05, 2011

News Industry News

Bayer AG: Phase III Study of Bayer’s Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy Endpoint

September 29, 2011

News Daily News

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Caitlin E. Cox

September 14, 2011

News Daily News

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

L.A. McKeown

September 13, 2011

News Industry News

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

September 08, 2011

News Conference News

ESC Congress 2011: Drugs, Devices Work Together

Caitlin E. Cox

September 06, 2011

News Conference News

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

August 31, 2011

News Conference News

Novel Anticoagulants Showing Benefits in A-fib Subgroups

August 29, 2011

News Conference News

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

August 28, 2011

Advertisement

Rivaroxaban May be Cost-Effective for A-fib Patients

El Rivaroxaban podría ser Rentable en Pacientes con Fibrilación Auricular

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

New Oral Anticoagulants Top Warfarin in A-fib Stroke Prevention

Los Nuevos Anticoagulantes Orales Superan a la Warfarina en la Prevención del ACV en pacientes con Fibrilación Auricular

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

ROCKET AF: Interrumpir la Toma de Rivaroxaban o Warfarina es Igual de Perjudicial en Pacientes con Fibrilación Auricular

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Hope Renewed for Novel Anticoagulant Use in ACS

Bayer AG: Phase III Study of Bayer’s Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy Endpoint

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

ESC Congress 2011: Drugs, Devices Work Together

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

Novel Anticoagulants Showing Benefits in A-fib Subgroups

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content